482 related articles for article (PubMed ID: 19010240)
1. Alemtuzumab induction in kidney transplantation: clinical results and impact on T-regulatory cells.
Morales J; Bono MR; Fierro A; Iñiguez R; Zehnder C; Rosemblatt M; Calabran L; Herzog C; Benavente D; Aguiló J; Pefaur J; Alba A; Ferrario M; Simon W; Contreras L; Buckel E
Transplant Proc; 2008 Nov; 40(9):3223-8. PubMed ID: 19010240
[TBL] [Abstract][Full Text] [Related]
2. Alemtuzumab induction in deceased donor kidney transplantation.
Shin M; Song SH; Kim JM; Kwon CH; Joh JW; Lee SK; Kim SJ
Transplant Proc; 2011; 43(6):2365-78. PubMed ID: 21839271
[TBL] [Abstract][Full Text] [Related]
3. Alemtuzumab induction therapy in highly sensitized kidney transplant recipients.
Lü TM; Yang SL; Wu WZ; Tan JM
Chin Med J (Engl); 2011 Mar; 124(5):664-8. PubMed ID: 21518554
[TBL] [Abstract][Full Text] [Related]
4. A randomized trial of alemtuzumab versus antithymocyte globulin induction in renal and pancreas transplantation.
Farney AC; Doares W; Rogers J; Singh R; Hartmann E; Hart L; Ashcraft E; Reeves-Daniels A; Gautreaux M; Iskandar SS; Moore P; Adams PL; Stratta RJ
Transplantation; 2009 Sep; 88(6):810-9. PubMed ID: 19920781
[TBL] [Abstract][Full Text] [Related]
5. Pilot study of rapid steroid elimination with alemtuzumab induction therapy in kidney and pancreas transplantation.
Sundberg AK; Roskopf JA; Hartmann EL; Farney AC; Rohr MS; Stratta RJ
Transplant Proc; 2005 Mar; 37(2):1294-6. PubMed ID: 15848701
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of late immunologic parameters among renal transplant recipients induced with Campath-1H.
Alba A; Morales J; Fierro A; Zehnder C; Cao C; Orozco R; Herzog C; Calabrán L; Contreras L; Buckel E
Transplant Proc; 2010; 42(1):253-6. PubMed ID: 20172322
[TBL] [Abstract][Full Text] [Related]
7. Alemtuzumab induction and antibody-mediated kidney rejection after simultaneous pancreas-kidney transplantation.
Pascual J; Pirsch JD; Odorico JS; Torrealba JR; Djamali A; Becker YT; Voss B; Leverson GE; Knechtle SJ; Sollinger HW; Samaniego-Picota MD
Transplantation; 2009 Jan; 87(1):125-32. PubMed ID: 19136902
[TBL] [Abstract][Full Text] [Related]
8. Alemtuzumab induction in kidney transplantation.
Huang E; Cho YW; Shah T; Peng A; Hayashi R; Bunnapradist S
Clin Transpl; 2005; ():343-54. PubMed ID: 17424750
[TBL] [Abstract][Full Text] [Related]
9. Alemtuzumab versus interleukin-2 receptor antibodies induction in living donor kidney transplantation.
Sampaio MS; Kadiyala A; Gill J; Bunnapradist S
Transplantation; 2009 Oct; 88(7):904-10. PubMed ID: 19935462
[TBL] [Abstract][Full Text] [Related]
10. Regulatory T cells and T cell depletion: role of immunosuppressive drugs.
Noris M; Casiraghi F; Todeschini M; Cravedi P; Cugini D; Monteferrante G; Aiello S; Cassis L; Gotti E; Gaspari F; Cattaneo D; Perico N; Remuzzi G
J Am Soc Nephrol; 2007 Mar; 18(3):1007-18. PubMed ID: 17287424
[TBL] [Abstract][Full Text] [Related]
11. A randomized trial of alemtuzumab vs. anti-thymocyte globulin induction in renal and pancreas transplantation.
Farney A; Sundberg A; Moore P; Hartmann E; Rogers J; Doares W; Jarrett A; Adams P; Stratta R
Clin Transplant; 2008; 22(1):41-9. PubMed ID: 18217904
[TBL] [Abstract][Full Text] [Related]
12. Pediatric living donor kidney transplantation under alemtuzumab pretreatment and tacrolimus monotherapy: 4-year experience.
Tan HP; Donaldson J; Ellis D; Moritz ML; Basu A; Morgan C; Vats AN; Erkan E; Shapiro R
Transplantation; 2008 Dec; 86(12):1725-31. PubMed ID: 19104412
[TBL] [Abstract][Full Text] [Related]
13. Subcutaneous administration of alemtuzumab in simultaneous pancreas-kidney transplantation.
Clatworthy MR; Sivaprakasam R; Butler AJ; Watson CJ
Transplantation; 2007 Dec; 84(12):1563-7. PubMed ID: 18165765
[TBL] [Abstract][Full Text] [Related]
14. The role of alemtuzumab in facilitating maintenance immunosuppression minimization following solid organ transplantation.
Agarwal A; Shen LY; Kirk AD
Transpl Immunol; 2008 Nov; 20(1-2):6-11. PubMed ID: 18824230
[TBL] [Abstract][Full Text] [Related]
15. Alemtuzumab induction with tacrolimus monotherapy in de novo renal transplantation.
Villanueva ME; Muñoz AS; Casasola CC; Africa JB; Danguilan RA; Ona ET
Transplant Proc; 2008 Sep; 40(7):2222-5. PubMed ID: 18790198
[TBL] [Abstract][Full Text] [Related]
16. Campath-1H (alemtuzumab) as an induction agent for the prevention of graft rejection and preservation of renal function in kidney transplant patients: Philippine 3-year follow-up.
Muñoz AS; Cabanayan-Casasola CB; Danguilan RA; Padua FB; Ona ET
Transplant Proc; 2008 Sep; 40(7):2230-3. PubMed ID: 18790200
[TBL] [Abstract][Full Text] [Related]
17. Alemtuzumab induction and triple maintenance immunotherapy in kidney transplantation from donors after cardiac death.
Schadde E; D'Alessandro AM; Knechtle SJ; Odorico J; Becker Y; Pirsch J; Sollinger H; Fernandez LA
Transpl Int; 2008 Jul; 21(7):625-36. PubMed ID: 18397178
[TBL] [Abstract][Full Text] [Related]
18. Sirolimus versus cyclosporine therapy increases circulating regulatory T cells, but does not protect renal transplant patients given alemtuzumab induction from chronic allograft injury.
Ruggenenti P; Perico N; Gotti E; Cravedi P; D'Agati V; Gagliardini E; Abbate M; Gaspari F; Cattaneo D; Noris M; Casiraghi F; Todeschini M; Cugini D; Conti S; Remuzzi G
Transplantation; 2007 Oct; 84(8):956-64. PubMed ID: 17989600
[TBL] [Abstract][Full Text] [Related]
19. Recipient memory-like lymphocytes remain unresponsive to graft antigens after CAMPATH-1H induction with reduced maintenance immunosuppression.
Trzonkowski P; Zilvetti M; Friend P; Wood KJ
Transplantation; 2006 Nov; 82(10):1342-51. PubMed ID: 17130784
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of induction therapy with alemtuzumab in kidney transplantation: a meta-analysis.
Shou ZF; Zhou Q; Cai JR; Cheng J; He Q; Wu JY; Chen JH
Chin Med J (Engl); 2009 Jul; 122(14):1692-8. PubMed ID: 19719973
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]